4Q25 & FY25 Earnings Call J a n u a r y 3 0 , 2 0 2 6 Forward-looking Statements 1 Value-first commercial approach continues to preserve ECU values 2 Announced Braskem long-term agreement, upgrading our export EDC values 3 Successful Epoxy volume growth amid European capacity closures 4 Winchester reduced commercial production accelerating destocking 5 Generated $321M of operating cash flow, keeping net debt flat year-over-year Chlor Alkali Products & Vinyls Segment Performance This presentation includes fo ...

Core Insights - Olin reported revenue of $1.67 billion for the quarter ended December 2025, a decrease of 0.4% year-over-year, with an EPS of -$0.58 compared to $0.09 in the same quarter last year [1] - The revenue exceeded the Zacks Consensus Estimate by 5.33%, while the EPS was slightly below the consensus estimate [1] Financial Performance - Olin's sales in the Epoxy segment reached $359.3 million, surpassing the average estimate of $293.07 million by 27.3% year-over-year [4] - Sales from Chlor Alkali Products and Vinyls were $856.4 million, slightly above the average estimate of $854.77 million, but represented a year-over-year decline of 10.2% [4] - Winchester sales amounted to $449.4 million, exceeding the estimated $406.54 million, reflecting a 3.2% increase compared to the previous year [4] Income Metrics - The income (loss) before taxes for Chlor Alkali Products and Vinyls was -$14.7 million, significantly below the average estimate of $46.26 million [4] - Winchester's income (loss) before taxes was $0.6 million, also below the average estimate of $7.84 million [4] - The income (loss) before taxes for the Epoxy segment was -$19.2 million, better than the average estimate of -$41.15 million [4] Stock Performance - Olin's shares have returned +9.2% over the past month, outperforming the Zacks S&P 500 composite, which saw a +0.8% change [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

分组1 - Olin reported a quarterly loss of $0.58 per share, aligning with the Zacks Consensus Estimate, compared to earnings of $0.09 per share a year ago, indicating a significant decline [1] - The company posted revenues of $1.67 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 5.33%, with no year-over-year revenue change [2] - Olin shares have increased by approximately 9.2% since the beginning of the year, outperforming the S&P 500's gain of 1.9% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$0.16 on revenues of $1.57 billion, while for the current fiscal year, it is $0.26 on revenues of $6.7 billion [7] - The Zacks Industry Rank for Chemical - Diversified is currently in the bottom 14% of over 250 Zacks industries, indicating potential challenges for the sector [8] - LyondellBasell, a competitor in the same industry, is expected to report a quarterly earnings decline of 76% year-over-year, with revenues projected to decrease by 26.5% from the previous year [9][10]

Financial Outlook - Olin Corporation announced an updated outlook for Q4 2025 on January 8, 2026[6] - The press release includes financial results and operational performance metrics for the fourth quarter ended December 31, 2025[6] - Specific financial figures and percentage changes will be detailed in the attached press release (Exhibit 99.1)[7]

Core Insights - Olin Corporation reported a net loss of $85.7 million for Q4 2025, a significant decline from a net income of $10.7 million in Q4 2024, reflecting ongoing market challenges and operational disruptions [1][2] - The company's adjusted EBITDA for Q4 2025 was $67.7 million, down from $193.4 million in Q4 2024, indicating a substantial decrease in operational profitability [1][27] - Total sales for Q4 2025 were $1,665.1 million, slightly lower than $1,671.3 million in Q4 2024, showing a stable revenue stream despite adverse conditions [1][21] Financial Performance - The full year 2025 reported a net loss of $42.8 million, compared to a net income of $108.6 million in 2024, highlighting a year-over-year decline in profitability [1][21] - Operating cash flow for Q4 2025 was $321.2 million, demonstrating effective cash generation despite the net loss [2] - The company ended 2025 with net debt of approximately $2.7 billion, maintaining a net debt to adjusted EBITDA ratio of 4.1 times, indicating a stable leverage position [12][32] Segment Performance - Chlor Alkali Products and Vinyls segment reported sales of $856.4 million in Q4 2025, down from $953.7 million in Q4 2024, primarily due to lower pricing [6][7] - The Epoxy segment saw sales increase to $359.3 million in Q4 2025 from $282.2 million in Q4 2024, driven by higher volumes, although it still reported a segment loss of $19.2 million [8] - Winchester segment sales were $449.4 million in Q4 2025, up from $435.4 million in Q4 2024, with military sales offsetting declines in commercial ammunition [9] Strategic Initiatives - The company is focused on its "Optimize the Core" strategic priorities, which include enhancing operational reliability and achieving structural cost reductions through the Beyond250 initiative, which has already realized $44 million in cost savings in 2025 [2][3] - Olin plans to close its epoxy resin manufacturing facility in Guarujá, Brazil, in Q1 2026, expecting to achieve annual structural cost savings of approximately $10 million [11] - The company anticipates that its Epoxy business will return to profitability in 2026, supported by new supply agreements and ongoing cost reduction efforts [3]

Core Viewpoint - Olin's shares experienced a significant rally of 5.8% to close at $23.86, attributed to higher trading volume and a recovery from a previous decline due to lowered EBITDA outlook [1][2]. Group 1: Company Performance - Olin's recent share price increase reflects a recovery from an initial shock after the company lowered its fourth-quarter EBITDA outlook, primarily due to a shortfall in its Chlor Alkali Products and Vinyls segment [2]. - The shortfall was caused by operational issues at the Freeport, TX facility, including extended maintenance, unplanned downtime, and lower demand for pipeline chlorine, but operations have since normalized [2]. - The company is focused on safe operations, cost reduction initiatives, and a disciplined value-first commercial approach [2]. Group 2: Financial Expectations - Olin is expected to report a quarterly loss of $0.28 per share, representing a year-over-year decline of 411.1%, with revenues projected at $1.62 billion, down 3% from the previous year [3]. - The consensus EPS estimate for Olin has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4]. Group 3: Industry Context - Olin operates within the Zacks Chemical - Diversified industry, where another company, Albemarle, closed 1.9% higher at $161.29 and has seen a 17.6% return over the past month [5]. - Albemarle's consensus EPS estimate has also remained unchanged, with a year-over-year change of +44% [6].

Core Viewpoint - Olin Corporation (OLN) has experienced a significant decline in share value, losing nearly 30% over the past year due to weak macroeconomic trends and low construction activity, particularly in China [1] Company Performance - Olin Corporation is a leading manufacturer of chemicals for PVC piping [1] - The company's stock performance has been negatively impacted by the overall downturn in the construction sector [1] Market Conditions - The construction activity has been low, especially in China, contributing to the challenges faced by Olin Corporation [1]

Core Insights - Olin Corporation (OLN) has revised its Q4 2025 adjusted EBITDA outlook to approximately $67 million, down from the previous guidance of $110-$130 million due to a shortfall in its Chlor Alkali Products and Vinyls segment [1][6] Group 1: Financial Performance - The Chlor Alkali Products and Vinyls unit generated revenues of $924 million in Q3, reflecting a year-over-year increase of around 6%, primarily driven by increased volume [3] - The decline in adjusted EBITDA expectations is attributed to operational issues at the Freeport, TX facility, including extended maintenance, unplanned downtime, and lower-than-expected demand for pipeline chlorine [2][6] Group 2: Operational Challenges - The Freeport facility faced significant operational disruptions, including an extended planned maintenance turnaround and interruptions in raw material supply, which negatively impacted performance towards the end of the quarter [2] - The facility has since returned to normal operations, alleviating some of the pressure on the segment [2][6] Group 3: Market Performance - Olin's shares have decreased by 27.3% over the past year, contrasting with a 20% decline in the industry [3] - The company is focusing on safe operations, cost reduction initiatives, and a disciplined value-first commercial approach to improve its performance [2][6]

Core Viewpoint - Innovent Biologics' partner Ollin has reported positive topline results from the Phase 1b JADE clinical study, indicating that OLN324, a next-generation VEGF/Ang2 bispecific antibody, shows superior efficacy compared to faricimab in treating diabetic macular edema (DME) and wet age-related macular degeneration (wAMD) [1][5]. Group 1: Clinical Study Results - OLN324 demonstrated faster and greater retinal drying compared to faricimab, with 4mg treated patients showing mean improvements in retinal drying that were approximately 75% greater at Week 1 and about 50% greater at Week 12 [2][3]. - Nearly 90% of patients treated with OLN324 4mg achieved absence of DME at Week 12, compared to 57% of faricimab patients [2]. - All treatment groups showed equivalent anatomic outcomes in wAMD, with sustained improvements in vision noted across both DME and wAMD treatment groups [3]. Group 2: Clinical Significance - The observed differences in speed and extent of retinal drying with OLN324 versus faricimab are considered clinically significant, potentially leading to broad utility for OLN324 across major retinal diseases [4]. - OLN324 is the first therapy to demonstrate superior anatomic efficacy compared to faricimab in a head-to-head clinical trial, validating its higher potency and dosing [5]. Group 3: Market Potential - OLN324 has the potential to become the new standard of care in the approximately $15 billion global market for retinal therapeutics [5]. - The successful results from the JADE Phase 1b trial position OLN324 favorably for future global Phase 3 studies in both DME and wAMD [5][6]. Group 4: Safety Profile - A favorable safety profile was observed with OLN324, with no cases of intraocular inflammation reported during the study, contrasting with one case in the faricimab group [9].

Core Viewpoint - Olin Corporation has revised its fourth quarter 2025 adjusted EBITDA outlook to approximately $67 million, significantly lower than the previous estimate of $110 to $130 million, primarily due to issues in the Chlor Alkali Products and Vinyls business [1][2]. Company Overview - Olin Corporation is a leading vertically integrated global manufacturer and distributor of chemical products, including chlorine, caustic soda, vinyls, and various other chemicals, as well as a major U.S. manufacturer of ammunition [3]. Financial Performance - The adjusted EBITDA for the fourth quarter 2025 is now expected to be around $67 million, a decrease from the earlier forecast of $110 to $130 million [1]. - The earnings shortfall is attributed to an extended planned maintenance turnaround and unplanned downtime at the Freeport, Texas operations, along with lower-than-expected pipeline chlorine demand [1][2]. Operational Challenges - The Chlor Alkali Products and Vinyls segment faced a significant decline in chlorine demand and operational issues at the Freeport site, which included a planned turnaround and interruptions in raw material supply from a third party [2]. - The Freeport site has since returned to normal operations, but the impact of these challenges has affected the overall financial outlook [2].